Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (IRST)
- Development stage
- Unknown
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
An autologous dendritic cell-based immunotherapy developed by IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori' for the treatment of glioblastoma. The vaccine is produced by isolating CD14+ monocytes from the patient via leukapheresis, differentiating them into dendritic cells using GM-CSF and IL-4, and then pulsing them with autologous tumor homogenate derived from the patient's surgically resected glioblastoma tissue. These cells are matured with a cytokine cocktail (TNFα, IL-1β, IL-6, and PGE2) before being administered intradermally. The goal is to stimulate a cytotoxic T lymphocyte response against a broad spectrum of patient-specific tumor antigens. It is currently being evaluated in the Phase II CombiG-Vax trial in combination with standard temozolomide chemotherapy.
- Other names
- Autologous Dendritic Cells (DC) vaccineautologous dendritic cells-Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS-glioblastoma
Beyond the preview
Go deeper on autologous dendritic cell vaccine (IRST).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (IRST).